Bionomics (BNO) - Merck thinks BNC375 is unforgettable, too | Analyst: Stuart Roberts | Rating: Buy TP:$1.10 | Bionomics has secured a new research...
Bionomics (BNO) - Merck thinks BNC375 is unforgettable, too | Analyst: Stuart Roberts | Rating: Buy TP:$1.10 | Bionomics has secured a new research collaboration with Merck & Co.. They have partnered with Bionomics on BNC375, which in pre-clinical has shown evidence that it can treat Alzheimer's disease as well as other disorders of the Central Nervous System (CNS). Merck will now fund all R&D related to BNC375, and will pay Bionomics US$20m upfront and US$506m in milestone payments to access the programme. This is a remarkable deal for a drug that has yet to be taken to the clinic and evidence both of the high demand for new Alzheimer's drugs from Big Pharma, and the quality of Bionomics' R&D in the CNS field.
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Over 30 years’ experience in the finance/tech industry. Mathan has worked extensively in all parts of the finance sector (i.e. County NatWest, Citi, LIM, Southern Cross, Bell Potter, Baillieu Holst and Blue Ocean Equities). Currently Founder and CEO at Deep Data Analytics (www.deepdataanalytics.com.au) which is an integrated data analytics driven investment strategy service provider.
3 topics
Comments
Comments
Sign In or Join Free to comment
most popular
Equities
This recently triggered market signal has never failed to predict gains
Ophir Asset Management